Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2013

01.06.2013 | Original Article

Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma

verfasst von: Luca Giovanella, Pierpaolo Trimboli, Frederik A. Verburg, Giorgio Treglia, Arnoldo Piccardo, Luca Foppiani, Luca Ceriani

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the relationship between serum thyroglobulin (Tg) levels, Tg doubling time (Tg-DT) and the diagnostic performance of 18F-FDG PET/CT in detecting recurrences of 131I-negative differentiated thyroid carcinoma (DTC).

Methods

Included in the present study were 102 patients with DTC. All patients were treated by thyroid ablation (e.g. thyroidectomy and 131I), and underwent 18F-FDG PET/CT due to detectable Tg levels and negative conventional imaging. Consecutive serum Tg measurements performed before the 18F-FDG PET/CT examination were used for Tg-DT calculation. The 18F-FDG PET/CT results were assessed as true or false after histological and/or clinical follow-up.

Results

Serum Tg levels were higher in patients with a positive 18F-FDG PET/CT scan (median 6.7 ng/mL, range 0.7–73.6 ng/mL) than in patients with a negative scan (median 1.8 ng/mL, range 0.5–4.9 ng/mL; P < 0.001). In 43 (88 %) of 49 patients with a true-positive 18F-FDG PET/CT scan, the Tg levels were >5.5 ng/mL, and in 31 (74 %) of 42 patients with a true-negative 18F-FDG PET/CT scan, the Tg levels were ≤5.5 ng/mL. A Tg-DT of <1 year was found in 46 of 49 patients (94 %) with a true-positive 18F-FDG PET/CT scan, and 40 of 42 patients (95 %) with a true-negative scan had a stable or increased Tg-DT. Moreover, combining Tg levels and Tg-DT as selection criteria correctly distinguished between patients with a positive and a negative scan (P<0.0001).

Conclusion

The accuracy of 18F-FDG PET/CT significantly improves when the serum Tg level is above 5.5 ng/mL during levothyroxine treatment or when the Tg-DT is less than 1 year, independent of the absolute value.
Literatur
1.
Zurück zum Zitat Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.PubMedCrossRef Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.PubMedCrossRef
2.
Zurück zum Zitat Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive and iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med. 2000;30:107–14.PubMedCrossRef Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive and iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med. 2000;30:107–14.PubMedCrossRef
3.
Zurück zum Zitat Freudenberg LS, Frilling A, Kühl H, Müller SP, Jentzen W, Bockisch A, et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol. 2007;17:3139–47.PubMedCrossRef Freudenberg LS, Frilling A, Kühl H, Müller SP, Jentzen W, Bockisch A, et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol. 2007;17:3139–47.PubMedCrossRef
4.
Zurück zum Zitat Iagaru A, Kalinyak JE, Mc Dougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med. 2007;32:690–5.PubMedCrossRef Iagaru A, Kalinyak JE, Mc Dougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med. 2007;32:690–5.PubMedCrossRef
5.
Zurück zum Zitat Miller ME, Chen Q, Elashoff D, Abemayor E, St John M. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck. 2011;33:562–5.PubMedCrossRef Miller ME, Chen Q, Elashoff D, Abemayor E, St John M. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck. 2011;33:562–5.PubMedCrossRef
6.
Zurück zum Zitat Lebolleaux S, Schroeder PR, Schlumberger M, Ladenson PV. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab. 2007;3:1112–21. Lebolleaux S, Schroeder PR, Schlumberger M, Ladenson PV. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab. 2007;3:1112–21.
7.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMedCrossRef Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMedCrossRef
8.
Zurück zum Zitat Treglia G, Muoio B, Salvatori M, Giovanella L. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol. 2012. doi:10.1007/s00405-012-2205-2. Treglia G, Muoio B, Salvatori M, Giovanella L. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol. 2012. doi:10.​1007/​s00405-012-2205-2.
9.
Zurück zum Zitat Menzel C, Zaplatnikov K, Diehl M, Döbert N, Hamscho N, Grünwald F. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun. 2004;25:239–43.PubMedCrossRef Menzel C, Zaplatnikov K, Diehl M, Döbert N, Hamscho N, Grünwald F. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun. 2004;25:239–43.PubMedCrossRef
10.
Zurück zum Zitat Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzweleski R, Hitzel A, et al. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid. 2010;20:15–23.PubMedCrossRef Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzweleski R, Hitzel A, et al. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid. 2010;20:15–23.PubMedCrossRef
11.
Zurück zum Zitat Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck. 2012;34:626–31.PubMedCrossRef Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck. 2012;34:626–31.PubMedCrossRef
12.
Zurück zum Zitat Bertagna F, Bosio G, Biasiotto G, Rodella C, Puta E, Gabanelli S, et al. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med. 2009;34:756–61.PubMedCrossRef Bertagna F, Bosio G, Biasiotto G, Rodella C, Puta E, Gabanelli S, et al. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med. 2009;34:756–61.PubMedCrossRef
13.
Zurück zum Zitat Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif BB, et al. 18FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48:221–6.PubMed Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif BB, et al. 18FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48:221–6.PubMed
14.
Zurück zum Zitat Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707–16.PubMedCrossRef Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707–16.PubMedCrossRef
15.
Zurück zum Zitat Wong H, Wong KP, Yau T, Tang V, Leung R, Chiu J, et al. Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? Ann Surg Oncol. 2012;19:3479–85.PubMedCrossRef Wong H, Wong KP, Yau T, Tang V, Leung R, Chiu J, et al. Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? Ann Surg Oncol. 2012;19:3479–85.PubMedCrossRef
16.
Zurück zum Zitat Greene FL, Gospodarowicz M, Wittekend C. American Joint Committee on Cancer (AJCC) staging manual. 7th ed. Philadelphia: Springer; 2009. Greene FL, Gospodarowicz M, Wittekend C. American Joint Committee on Cancer (AJCC) staging manual. 7th ed. Philadelphia: Springer; 2009.
17.
Zurück zum Zitat Giovanella L, Keller F, Ceriani L, Tozzoli R. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med. 2009;47:952–4.PubMed Giovanella L, Keller F, Ceriani L, Tozzoli R. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med. 2009;47:952–4.PubMed
18.
Zurück zum Zitat Bidart M, Thullier F, Augereau C, Chalas J, Daver A, Jacob N, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem. 1999;45:1695–707.PubMed Bidart M, Thullier F, Augereau C, Chalas J, Daver A, Jacob N, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem. 1999;45:1695–707.PubMed
19.
Zurück zum Zitat Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342–8.PubMedCrossRef Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342–8.PubMedCrossRef
20.
Zurück zum Zitat Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71–6.PubMed Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42:71–6.PubMed
21.
Zurück zum Zitat Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging. 2008;35:950–7.PubMedCrossRef Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging. 2008;35:950–7.PubMedCrossRef
22.
Zurück zum Zitat Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527–33.PubMedCrossRef Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527–33.PubMedCrossRef
Metadaten
Titel
Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma
verfasst von
Luca Giovanella
Pierpaolo Trimboli
Frederik A. Verburg
Giorgio Treglia
Arnoldo Piccardo
Luca Foppiani
Luca Ceriani
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2013
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2370-6

Weitere Artikel der Ausgabe 6/2013

European Journal of Nuclear Medicine and Molecular Imaging 6/2013 Zur Ausgabe